Merck & Co., Inc. (MRK) AI Stock Analysis

Merck & Co., Inc. operates through two principal segments: Pharmaceutical and Animal Health. The Pharmaceutical division develops and markets human healthcare therapies spanning oncology, hospital acute care, immunology, cardiovascular conditions, diabetes, and vaccines for preventive care. The Animal Health unit supplies veterinary pharmaceuticals, vaccines, health management software, and digital identification and monitoring tools. Merck serves drug wholesalers, hospitals, government agencies, managed healthcare providers, veterinarians, and animal producers. The firm also maintains partnerships with entities such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. to jointly develop and commercialize long-acting HIV therapies.

Between FY2020 and FY2025, Merck grew revenue at a 5-year CAGR of 9.4%. Revenue rose from $48.70B in FY2021 to $64.93B in FY2025, alongside net income growth from $13.05B to $18.25B. Operating margin expanded to 36.2% in FY2025, while gross margin stood at 72.0%. Across the trailing twelve months, revenue reached $66.57B, but operating margin declined to -0.2% and profit margin fell to 4.8%. In the latest quarter ending June 30, 2026, quarterly revenue increased 5.1% year-over-year, while quarterly earnings contracted 19.3% year-over-year.

As of June 30, 2026, Merck carried $7.14B in cash and short-term investments against $53.91B in total debt, resulting in net debt of $46.77B. Shareholders' equity was $41.93B, yielding a debt-to-equity ratio of 1.29 and a current ratio of 1.32. In FY2025, the company generated $16.47B in operating cash flow and $12.36B in free cash flow. Merck allocated capital toward $4.11B in capital expenditures, $5.08B in share buybacks, and $8.18B in dividends paid.

Merck trades at a trailing price-to-earnings multiple of 115.8x, above the 27.2x median of its S&P 500 Healthcare peers. Its forward P/E of 15.3x sits below the peer median of 16.6x, while its EV/EBITDA of 10.0x compares favorably to the peer median of 15.7x. The company holds a price-to-sales ratio of 5.4x compared to the peer median of 3.4x. Merck's 1-year return of 79.0% significantly outperformed the SPY return of 16.8%, and its 5-year return of 117.1% surpassed the SPY return of 83.0%.

Merck pays an annual forward dividend of $3.40 per share, which equates to a dividend yield of 2.33%. The dividend payout ratio stands at 105.9%, with distributions paid quarterly. Merck has paid consecutive dividends for 57 years and generated a 5-year annualized dividend growth rate of 6.7%. The most recent ex-dividend date occurred on September 15, 2026.

Wall Street coverage includes 14 Strong Buy, 5 Buy, and 8 Hold ratings, with zero Sell or Strong Sell ratings. The mean price target is $158.44, representing an 8.6% upside from the last close of $145.95. For the current fiscal year ending December 31, 2026, analysts estimate EPS of $2.66 on revenue of $67.04B. For the next fiscal year, 22 analysts project EPS of $9.29 and revenue of $69.93B. Merck has beaten EPS estimates in each of the last 4 quarters, with next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Merck & Co., Inc. (MRK). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MRK income statement, MRK balance sheet, MRK key metrics, MRK analyst forecast, MRK chart. See the MRK stock overview for the latest quote and news.